NeuroOne Medical Technologies Corp当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名89/208位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价2.23。中期看,股价处于下降通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
NeuroOne Medical Technologies Corp评分
相关信息
行业排名
89 / 208
全市场排名
214 / 4582
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
强力买入
评级
2.225
目标均价
+239.69%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
NeuroOne Medical Technologies Corp亮点
亮点风险
NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
公司代码NMTC
公司NeuroOne Medical Technologies Corp
CEORosa (David A)
网址https://nmtc1.com/
常见问题
NeuroOne Medical Technologies Corp(NMTC)的当前股价是多少?
NeuroOne Medical Technologies Corp(NMTC)的当前股价是 0.734。
NeuroOne Medical Technologies Corp的股票代码是什么?
NeuroOne Medical Technologies Corp的股票代码是NMTC。
NeuroOne Medical Technologies Corp股票的52周最高点是多少?
NeuroOne Medical Technologies Corp股票的52周最高点是1.390。
NeuroOne Medical Technologies Corp股票的52周最低点是多少?
NeuroOne Medical Technologies Corp股票的52周最低点是0.395。
NeuroOne Medical Technologies Corp的市值是多少?
NeuroOne Medical Technologies Corp的市值是36.58M。
NeuroOne Medical Technologies Corp的净利润是多少?
NeuroOne Medical Technologies Corp的净利润为-12.32M。
现在NeuroOne Medical Technologies Corp(NMTC)的股票是买入、持有还是卖出?
根据分析师评级,NeuroOne Medical Technologies Corp(NMTC)的总体评级为--,目标价格为2.225。
NeuroOne Medical Technologies Corp(NMTC)股票的每股收益(EPS TTM)是多少
NeuroOne Medical Technologies Corp(NMTC)股票的每股收益(EPS TTM)是-0.166。